IDH2 and hematologic disorder: Additionally, Agios is also pursuing a phase I clinical trials for AG-881 (Vorasidenib) (Compound 6), a brain penetrant and pan mutant IDH selective inhibitor in advanced solid tumors including gliomas with IDH1 and/or IDH2 mutation (NCT02481154) and for advanced hematologic malignancies (NCT02492737).